Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 7 results for "nirmal bang institutional equities"

Here are top trading ideas from Rahul Arora

In an interview to CNBC-TV18's Prashant Nair and Sumaira Abidi, Rahul Arora, CEO at Nirmal Bang Institutional Equities shared his readings and outlook on market and specific stocks. Money Control, 3 weeks ago

2 images for "nirmal bang institutional equities"

International Business Times India, 3 months ago
Financial Express, 8 months ago

Sikka's 'warrior' quip: Analyst warns Infosys strife may worsen

Speaking to CNBC-TV18, Girish Pai, Head of Research at Nirmal Bang Institutional Equities, said it was clear that there is still friction between the Infosys board and the company's founders.
 Money Control1 month ago

Is market in bubble land already? Pundits don’t think so

Bulge bracket overseas investors are back. And they are buying. The S&P BSE Sensex advanced 4.1 percent in February as offshore fund managers ended four months of sales to invest a net $1.4 billion in local stocks. After being net sellers in both equity (Rs ...
 The Financial Chronicle3 weeks ago

‘Focus Should Be To Keep Cost Of Capital Low’

A look at the mix of earnings of Nifty constituents indicates that India’s budget has only a limited direct impact, but has a larger indirect impact through cost of capital and INR/USD rate. A large part of Nifty earnings (50 per cent to 60 per cent) are ...
 The Financial Chronicle2 months ago

Margins, financial services biz big positives from Infosys: Pro

Girish Pai, head of research at Nirmal Bang Institutional Equities said that the guidance revision is a definite positive in the short-term. However, he is more worried for medium and long-term growth on both structural and cyclical parameters.
 Money Control2 months ago See margins falling 100-350 bps for IT on likely H1B hike: Pro  Money Control2 months ago

Price erosion won't impact generic cos in US: Dishman Pharma

Pharmaceutical stocks have been under the US FDA cloud. Will 2017 fare better? CNBC-TV18's Latha Venkatesh Sonia Shenoy asks Arpit Vyas, MD of Dishman Pharmaceuticals Chemicals, Surajit Pal of Prabhudas Lilladher and Vishal Manchanda of Nirmal Bang ...
 Money Control2 months ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less